Challice L. Bonifant

Challice L. Bonifant

Auto-generated profile, based on publicly available information

Challice L. Bonifant

16Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
CBChallice L Bonifant
Challice L Bonifant
HJHollie J Jackson
Hollie J Jackson
RBRenier J Brentjens
Renier J Brentjens
KCKevin J Curran
Kevin J Curran
MTO is an international, online-only, open-access journal focusing on the development and clinical testing of molecular therapies targeting cancer

12 December 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ICIlias Christodoulou
Ilias Christodoulou
WHWon Jin Ho
Won Jin Ho
AMAndrew Marple
Andrew Marple
JRJonas W Ravich
Jonas W Ravich
ATAda Tam
Ada Tam
CBChallice L Bonifant
Challice L Bonifant
Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia (AML) remains poor and cell-based immunotherapies hold promise to improve outcomes. Natural Killer (NK) cells can elicit an antileukemic response via a repertoire of activating receptors that bind AML surface ligands. NK-cell adoptive transfer is safe but thus far has shown limited anti-AML efficacy. Here, we aimed to overcome this limitation by engineering NK cells to express chimeric antigen receptors (CARs) to boost their anti-AML activity and interleukin (IL)-15 to enhance their persistence. Methods We characterized in detail NK-cell populations expressing a panel of AML (CD123)-specific CARs and/or IL-15 in vitro and in AML xenograft models. Results CARs with 2B4.ζ or 4-1BB.ζ signaling domains demonstrated greater cell surface expression and endowed NK cells with improved anti-AML activity in vitro. Initial in vivo testing revealed that only 2B4.ζ Chimeric Antigen Receptor (CAR)-NK cells had improved anti-AML activity in comparison to untransduced (UTD) and 4-1BB.ζ CAR-NK cells. However, the benefit was transient due to limited CAR-NK-cell persistence. Transgenic expression of secretory interleukin (sIL)-15 in 2B4.ζ CAR and UTD NK cells improved their effector function in the setting of chronic antigen simulation in vitro. Multiparameter flow analysis after chronic antigen exposure identified the expansion of unique NK-cell subsets. 2B4.ζ/sIL-15 CAR and sIL-15 NK cells maintained an overall activated NK-cell phenotype. This was confirmed by transcriptomic analysis, which revealed a highly proliferative and activated signature in these NK-cell groups. In vivo, 2B4.ζ/sIL-15 CAR-NK cells had potent anti-AML activity in one model, while 2B4.ζ/sIL-15 CAR and sIL-15 NK cells induced lethal toxicity in a second model. Conclusion Transgenic expression of CD123-CARs and sIL-15 enabled NK cells to function in the setting of chronic antigen exposure but was associated with systemic toxicities. Thus, our study provides the impetus to explore inducible and controllable expression systems to provide cytokine signals to AML-specific CAR-NK cells before embarking on early-phase clinical testing.

4 January 2018 in Blood
Verified
Journal Article
Open access
PDF file
MVMireya Paulina Velasquez
Mireya Paulina Velasquez
CBChallice L. Bonifant
Challice L. Bonifant
SGStephen Gottschalk
Stephen Gottschalk
There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this need, because it does not rely on the cytotoxic mechanism of conventional therapies. Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an “off-the-shelf” product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell engager blinatumomab has emerged as the most successful BsAb to date. It consists of 2 single-chain variable fragments specific for CD19 present on B-cell malignancies and CD3 expressed on almost all T cells. Blinatumomab has shown potent antitumor activity as a single agent, particularly for acute lymphoblastic leukemia, resulting in its US Food and Drug Administration approval. However, although successful in inducing remissions, these are normally short-lived, with median response durations of <1 year. Nevertheless, the success of blinatumomab has reinvigorated the BsAb field, which is bustling with preclinical and clinical studies for not only B-cell–derived lymphoblastic leukemia and lymphoma but also acute myeloid leukemia and multiple myeloma. Here, we will review the successes and challenges of T-cell–targeted BsAbs for the immunotherapy of hematological malignancies with special focus on conducted clinical studies and strategies to improve their efficacy.

1 January 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
JKJung-Sik Kim
Jung-Sik Kim
CLCarolyn Lee
Carolyn Lee
CBChallice L. Bonifant
Challice L. Bonifant
HRHabtom Ressom
Habtom Ressom
TWTodd Waldman
Todd Waldman
In an effort to identify genes whose expression is regulated by activated phosphatidylinositol 3-kinase (PI3K) signaling, we performed microarray analysis and subsequent quantitative reverse transcription-PCR on an isogenic set of PTEN gene-targeted human cancer cells. Numerous p53 effectors were upregulated following PTEN deletion, including p21, GDF15, PIG3, NOXA, and PLK2. Stable depletion of p53 led to reversion of the gene expression program. Western blots revealed that p53 was stabilized in HCT116 PTEN−/− cells via an Akt1-dependent and p14ARF-independent mechanism. Stable depletion of PTEN in untransformed human fibroblasts and epithelial cells also led to upregulation of p53 and senescence-like growth arrest. Simultaneous depletion of p53 rescued this phenotype, enabling PTEN-depleted cells to continue proliferating. Next, we tested whether oncogenic PIK3CA, like inactivated PTEN, could activate p53. Retroviral expression of oncogenic human PIK3CA in MCF10A cells led to activation of p53 and upregulation of p53-regulated genes. Stable depletion of p53 reversed these PIK3CA-induced expression changes and synergized with oncogenic PIK3CA in inducing anchorage-independent growth. Finally, targeted deletion of an endogenous allele of oncogenic, but not wild-type, PIK3CA in a human cancer cell line led to a reduction in p53 levels and a decrease in the expression of p53-regulated genes. These studies demonstrate that activation of PI3K signaling by mutations in PTEN or PIK3CA can lead to activation of p53-mediated growth suppression in human cells, indicating that p53 can function as a brake on phosphatidylinositol (3, 4, 5)-triphosphate-induced mitogenesis during human cancer pathogenesis.

10 June 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PSPaul J. Shami
Paul J. Shami
JSJoseph E. Saavedra
Joseph E. Saavedra
CBChallice L. Bonifant
Challice L. Bonifant
JCJingxi Chu
Jingxi Chu
VUVidya Udupi
Vidya Udupi
LKLarry K. Keefer
Larry K. Keefer

11 April 2001 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
JSJoseph E. Saavedra
Joseph E. Saavedra
ASAloka Srinivasan
Aloka Srinivasan
CBChallice L. Bonifant
Challice L. Bonifant
JCJingxi Chu
Jingxi Chu
ASAnna P. Shanklin
Anna P. Shanklin
LKLarry K. Keefer
Larry K. Keefer